Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gefapixant Phase 3 Study in Chronic Cough (PN030)
NCT04525885Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- May 2019
- Primary completion
- Sep 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of gefapixant in chronic cough, sponsored by Merck & Co.. Started May 2019; status: completed.
02
Drugs
gefapixant
03
Conditions
chronic cough
Beyond the preview
Go deeper on NCT04525885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04525885.